Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet®) versus calcipotriol (Daivonex®) in the treatment of psoriasis vulgaris: A randomized, multicentre, clinical trial

Journal of Dermatological Treatment

Volumn 18, Issue 6, 2007, Pages 361-365

  Saraceno, Rosita ^a,j   Andreassi, Lucio ^b   Ayala, Fablo ^c   Bongiorno, Maria Rita ^d   Giannetti, Alberto ^e   Lisi, Paolo ^f   Martini, Patrizia ^g   Peris, Ketty ^h   Peserico, Andrea ⁱ   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF PERUGIA   (Italy)

^g CAMPO DI MARTE HOSPITAL   (Italy)

^h UNIVERSITY OF L'AQUILA   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

Calcipotriol; Calcipotriol betamethasone dipropionate; PASI; Psoriasis; Skindex 29; Two compound product

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL;

ADULT; AGED; ARTICLE; BURN; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 36849008096     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701646156     Document Type: Article

References (18)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899-912.
2. Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol. 2007 (in press).
3. Kragballe K, Corvari L. An innovation in topical therapy: Insights from international dermatologists. Cutis. 2007;79(s2):39-45.
4. Norman AW, Bouillon R, Thomasset M. Vitamin D gene regulation structure function analysis and clinical application. Proceedings of the Eighth Workshop on Vitamin D. Berlin: de Gruyter; 1991.
5. Cather J, Menter A. Novel therapies for psoriasis. Am J Clin Dermatol. 2002;3:159-73.
6. Guenther L, van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, doubleblind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147:316-23.
7. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.
8. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate and calcipotriol in psoriasis vulgaris. Acta Derm Venerol. 2002;82:131-5.
9. Van de Kerkhof PC. The impact of a two compound product containing calcipotriol and betamethasone dipropionate (Daivobet®/Dovobet®) on the quality of life in patients with psoriasis vulgaris: A randomized controlled trial. Br J Dermatol. 2004;151:663-8.
10. Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: A randomised, double-blind trial. Dermatology. 2004;209:308-13.
11. Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone valerate in patients with psoriasis vulgaris. J Am Acad Dermatol. 1992;26(5 Pt 1):736-43.
12. Kragballe K, Gjertesen BT, de Hoop D, Karlsmark T, van de Kerkhof PC, Larko O, et al. Double blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet. 1991;337:193-6.
13. Van de Kerkhof PC, Franssen M, de La Brassine M, Kuipers M. Calcipotriol cream in the morning and ointment in the evening: A novel regimen to improve compliance. J Dermatol Treatment. 2001;12:75-9.
14. Duweb GA, Eldebani S, Alhaddar J. Calcipotriol cream in the treatment of flexural psoriasis. Int J Tissue React. 2003;25:127-30.
15. Carboni I, de Felice C, Bergamin A, Chimenti S. Topical use of calcitriol 3 mg/g ointment in the treatment of mild-to-moderate psoriasis. J Eur Acad Dermatol Venereol. 2005;19 Suppl 3:11-13.
16. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978;157:238-44.
17. Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM. Further evidence of the validity and reliability of the SKINDEX-29: An Italian study on 2,242 dermatological outpatients. Dermatology. 2002;204:43-9.
18. Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology. 2006;213:319-26.